

Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

<https://marketpublishers.com/r/D2A7661CB930EN.html>

Date: December 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: D2A7661CB930EN

Abstracts

The Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:

Major Highlights

This report delivers a comprehensive overview of the Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

DENGUE PIPELINE ANALYSIS

- Dengue is a mosquito-borne infectious disease caused by the dengue virus, which is typically a single positive-stranded RNA virus.
- Dengue is transmitted through the bite of infected Aedes mosquito, mainly Aedes aegypti and Aedes albopictus. This can be transmitted through exposure to infected blood, organs, or other tissues.
- The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus causing dengue belongs to the Flavivirus genus of the Flaviviridae family.
- Symptoms of dengue include a headache, fatigue, high fever, muscle pain, anemia, diarrhea, skin rashes, and vomiting.
- Severe dengue will cause seizures, yellow skin, coma, or death. Dengue causes CNS manifestations, which includes any degree of impaired consciousness, abnormal neurological signs, delirium, and focal and generalized convulsions.
- It can also cause dengue shock syndrome, which shows massive bleeding and shock. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. Treatment includes the use of analgesics, fluid replacement therapy, and a healthy lifestyle.
- Even though a vaccine for treating dengue is available now, which is a significant achievement, its long-term protective efficacy against 4-dengue virus serotypes also remains to be definitively determined.
- There are different causes underlying the clinical event of dengue for which multimodal and effective treatment approach is required. Among all the effective treatments available, vaccines are considered as the best available precaution option for dengue.
- Several vaccines currently under clinical trials are showing promising effects that include TVD, TV003, TV005, TVDV, and TDENV. Expected approval for the vaccine TV003 (by Butantan Institute.) a live attenuated vaccine is likely to drive the market in the next few years.
- In terms of product, the market has been categorized into only one product, i.e. CYD-TDV (Dengvaxia) as only one vaccine of Sanofi Pasteur is approved in the market.
- Drugs are a complementary intervention that may be useful for patients who contract dengue if they did not receive an approved vaccine for dengue or for whom vaccination was ineffective.
- These drugs are at various stages of clinical development. However, no antivirals have been developed exclusively for dengue has entered into the clinical trials. balapiravir is the only drug that is deemed to directly target one of the viral proteins (NS5) and has been clinically investigated.

- This nucleoside analog, developed by Roche Pharmaceutical for hepatitis C, was also examined as a short-course treatment against dengue because of its useful short-course safety profile.
- This compound, however, did not meet the efficacy endpoint, because of altered host cell kinase expression or activity during dengue infection.
- Although no antiviral agent has been found yet now to be effective against acute dengue in proof-of-concept trials, the therapeutic pipeline development still contains several compounds and biologics that will be soon clinically evaluated. Some of phase III clinical pipeline biologics include tetravalent dengue vaccine (TDV), Yellow fever vaccine (YF-17D) developing by Takeda, CYD Dengue vaccine, HAV vaccine, Human Papillomavirus Bivalent vaccine are going to increase the future dengue market growth.
- Rising prevalence of diseases, increasing company initiatives to enhance R&D are driving the growth of the vaccines market, increasing government and non-government funding for vaccine development, and.
- On the other hand, market growth may be hampered due to the high cost of vaccine development. Raising awareness about symptoms of dengue fever and raising government initiatives to provide better healthcare facilities provides ample opportunities for the market growth.
- Rapid urbanization, lack of sanitation, increase in international trade and mobility of population restraint the efforts to control dengue.

I would like to order

Product name: Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook
(2024-2031) 2026

Product link: <https://marketpublishers.com/r/D2A7661CB930EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/D2A7661CB930EN.html>